음성 조절 분자

P53 responds to DNA damage by halting the cell cycle and recruiting enzymes to repair the damage. If the damage is irreparable, P53 triggers apoptosis, or cell death, preventing the damaged DNA from being duplicated. This protective mechanism is critical for maintaining genomic integrity and preventing cancer development.

P21 is a CDK inhibitor produced in response to increased P53 levels. It binds directly to CDK/cyclin complexes, blocking their activity and preventing the cell from transitioning from G1 to S phase. This inhibition pauses the cell cycle until conditions are appropriate for DNA replication to proceed.

Active, dephosphorylated retinoblastoma protein binds to transcription factors such as E2F, blocking their ability to initiate gene transcription. This prevents production of proteins required for the G1 to S transition. When the cell reaches sufficient size, Rb becomes phosphorylated, releases E2F, and allows necessary genes to be transcribed.

Negative regulators like P53, P21, and Rb prevent uncontrolled cell replication by enforcing cell cycle checkpoints and triggering apoptosis when needed. Faulty copies of these proteins are found in cancer cells with uncontrolled replication. Understanding these regulatory mechanisms reveals how their dysfunction contributes to cancer development.

As a cell grows larger, retinoblastoma protein is gradually phosphorylated until it becomes inactivated and detaches from E2F. This size-dependent inactivation allows the cell to progress through the G1 checkpoint only after reaching sufficient size for division. The mechanism ensures cells divide at appropriate intervals relative to their growth.

When P53 detects DNA damage during G1, it recruits repair enzymes to fix the damage before the cell transitions to S phase. Simultaneously, P53 stimulates production of P21, which inhibits CDK/cyclin complexes and arrests the cell cycle. This pause allows time for successful DNA repair before replication begins.

Negative regulators pause or terminate cell cycle progression until specific criteria are met, such as DNA integrity or adequate cell size. Positive regulators advance cells through checkpoints. Together, they balance cell cycle control: negative regulators enforce quality checkpoints while positive regulators drive progression when conditions permit.